Showing results (681-690 of 746) with videos related to

Sort By:
Pageof 75
Blood|September 24, 2024
Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINEJennifer R Brown, Barbara Eichhorst, Nicole Lamanna, et al.
Diabetes|February 21, 2013
Targeting pyruvate carboxylase reduces gluconeogenesis and adiposity and improves insulin resistanceNaoki Kumashiro, Sara A Beddow, Daniel F Vatner, et al.
Cell|January 21, 2014
Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switchPaul Cohen, Julia D Levy, Yingying Zhang, et al.
Cell|February 10, 2015
Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetesRachel J Perry, João-Paulo G Camporez, Romy Kursawe, et al.
Diabetes|March 29, 2024
Role of Cardiorespiratory Fitness and Mitochondrial Oxidative Capacity in Reduced Walk Speed of Older Adults With DiabetesSofhia V Ramos, Giovanna Distefano, Li-Yung Lui, et al.
Bone Marrow Transplantation|July 10, 2002
High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research GroupJ Czyz, A Hellmann, R Dziadziuszko, et al.
Leukemia & Lymphoma|July 7, 2018
Hodgkin lymphoma of the elderly patients: a retrospective multicenter analysis from the Polish Lymphoma Research Group.Tomasz Wróbel, Przemysław Biecek, Justyna Rybka, et al.
Cell|October 15, 2013
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cellsWilliam J Israelsen, Talya L Dayton, Shawn M Davidson, et al.
Blood Advances|November 1, 2021
Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignanciesConstantine S Tam, Meletios Dimopoulos, Ramon Garcia-Sanz, et al.
The Lancet. Haematology|June 12, 2026
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trialUmberto Vitolo, Juan Miguel Bergua Burgues, Johannes Duell, et al.
Pageof 75